{{Rsnum
|rsid=2284018
|Gene=CACNG2
|Chromosome=22
|position=36701519
|Orientation=plus
|GMAF=0.2525
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CACNG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 57.8 | 36.7 | 5.5
| HCB | 48.1 | 41.4 | 10.5
| JPT | 44.0 | 46.8 | 9.2
| YRI | 70.9 | 27.0 | 2.1
| ASW | 69.6 | 28.6 | 1.8
| CHB | 48.1 | 41.4 | 10.5
| CHD | 48.1 | 42.3 | 9.6
| GIH | 50.5 | 36.6 | 12.9
| LWK | 72.0 | 25.2 | 2.8
| MEX | 0.0 | 0.0 | 0.0
| MKK | 69.5 | 28.5 | 2.0
| TSI | 51.0 | 41.0 | 8.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2284018
|Name_s=
|Gene_s=CACNG2
|Feature=
|Evidence=PubMed ID:18408563
|Annotation=The C allele of this variant is associated with increased response of patients with bipolar disorder to lithium treatment relative to that observed in patients carrying two copies of the T allele. This association was seen in one cohort of 161 patients, but not in a separate cohort of 197 patients.
|Drugs=lithium
|Drug Classes=
|Diseases=Bipolar Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA161659505
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2284018
|overall_frequency_n=29
|overall_frequency_d=126
|overall_frequency=0.230159
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24581832
|Title=Exploring the associations between genetic variants in genes encoding for subunits of calcium channel and subtypes of bipolar disorder
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}